Magnesium benefits heart patients
LOS ANGELES, CALIFORNIA. The health of the lining (endothelium) of the blood vessels is
crucial to
cardiovascular health. There is considerable evidence that a dysfunction of the endothelium can
lead to
atherosclerosis and subsequent coronary artery disease (CAD). Researchers at the Cedars-
Sinai Medical
Center now report that oral magnesium supplementation can substantially reduce endothelial
dysfunction
and improve exercise tolerance in CAD patients. The randomized, prospective, double blind,
placebo-
controlled trial involved 50 patients (41 men and 9 women with a mean age of 67 years) who had
been
diagnosed with CAD either by angiography or after having had a heart attack. Initial evaluation of
the
patients showed that 72 per cent of them had a lower than normal tissue magnesium level. The
tissue
magnesium level was measured in sublingual epithelial cells scraped from under the tongue or
from
between the gums and the upper or lower lips. Magnesium levels measured in sublingual cells
have been
found to correlate well with levels found in heart tissue.
The patients were randomized to receive either a placebo or 365 mg of elemental magnesium (in
the form of
oxide and carbonate) daily. After six months tissue magnesium concentration was measured
again, a
treadmill test was performed, and endothelial function was evaluated using ultrasound. Patients
in the
magnesium group increased their intracellular magnesium level by about 10 per cent to reach the
lower limit
of the normal range. Endothelial function (flow-mediated vasodilation measured at the brachial
artery)
improved by 25 per cent in the magnesium group as compared to a 4.5 per cent decline in the
placebo
group over the six-month period. The magnesium supplemented group also performed
significantly better
on the treadmill test than did the placebo group. Not only did they improve their exercise duration
as
compared to baseline and the placebo group, but it was also highly significant that none of them
experienced an arrhythmia during the test whereas four patients in the placebo group did.
The researchers suggest that magnesium may protect the heart against the detrimental effects of
a calcium
overload and may improve intracellular ATP production and glucose use. They conclude that oral
magnesium supplementation improves exercise tolerance and endothelial function in coronary
artery
disease patients. NOTE: This study was partially funded by Asta Medica Company, Inc. (Vienna,
Austria)
the manufacturer of the magnesium supplement.
Shechter, Michael, et al. Oral magnesium therapy improves endothelial function in patients with
coronary
artery disease. Circulation, Vol. 102, November 7, 2000, pp. 2353-58
Magnesium and heart surgery in children
CHARLESTON, SOUTH CAROLINA. Administration of magnesium has been shown to reduce
the
incidence of heart surgery related arrhythmias in adults. It has also been observed that the
magnesium
level in the right atrial tissue is lower in adult patients with postoperative cardiac arrhythmias
compared to
patients without arrhythmias after heart surgery. Researchers at the Department of Pediatric
Cardiology at
the Medical University of South Carolina now report that children undergoing surgery for
congenital heart
defects develop a severe magnesium deficiency immediately after surgery. This deficiency is
associated
with a greater incidence of a serious arrhythmia (junctional ectopic tachycardia) and can be
prevented by an
infusion of magnesium sulfate immediately after completion of the surgery.
The study involved 28 pediatric patients (average age of five years) who were scheduled to
undergo heart
surgery with cardiopulmonary bypass (CPB). The patients were randomly assigned to receive an
infusion of
magnesium (30 mg/kg body weight of a five per cent saline solution administered over a period of
10
minutes) or an infusion of saline solution immediately after cessation of CPB. Blood levels of
magnesium
were measured in all patients before surgery, before CPB, after CPB, upon arrival in the intensive
care unit
(ICU), and then every four hours for 24 hours. Each patient was also monitored for arrhythmias
for 24 hours
with a Holter monitor.
Comparison of the results for the two treatment groups revealed that the magnesium level was
significantly
below normal in patients who had received saline solution (placebo) when they arrived in the ICU
and for the
following 20 hours. Patients who had received the magnesium infusion, on the other hand, had
magnesium
levels that were well within the normal range (1.6 to 2.3 mg/dL) when tested in the ICU and for
the following
20 hours. There were no incidences of junctional ectopic tachycardia in the magnesium group,
but four (27
per cent) of the patients in the placebo group experienced this serious arrhythmia. It stopped
after a
magnesium infusion. The researchers "recommend routine measurement of magnesium levels
after CPB in
children undergoing heart surgery, with timely magnesium supplementation in the postoperative
period." [49
references]
Dorman, B. Hugh, et al. Magnesium supplementation in the prevention of arrhythmias in pediatric
patients
undergoing surgery for congenital heart defects. American Heart Journal, Vol. 139, No. 3, 2000,
pp. 522-
28
Supplement recommendations for chronic fatigue syndrome
BERKELEY, CALIFORNIA. Dr. Melvyn Werbach, MD of the UCLA School of Medicine has just
published a
thorough review of nutritional deficiencies involved in chronic fatigue syndrome (CFS). These
include
deficiencies in vitamin C, coenzyme Q10, magnesium, zinc, sodium, l-tryptophan, l-carnitine,
essential fatty
acids, and various B vitamins. He points out that there is some evidence that the deficiencies are
caused by
the disease itself rather than by an inadequate diet. He suggests that the deficiencies not only
contribute to
the symptoms of CFS but also impair the healing process. Although the results of
supplementation trials
involving CFS patients have been inconclusive so far Dr. Werbach nevertheless recommends
that CFS
patients be given large doses of certain supplements for at least a trial period to see if their
symptoms
improve. His recommendations are:
- Folic acid: 1-10 mg/day for 3 months
- Vitamin B12: 6-70 mg (intramuscular injection) per week for 3 weeks
- Vitamin C: 10-15 grams/day
- Magnesium: 600 mg/day + 2400 mg/day of malic acid for 8 weeks
- Zinc: 135 mg/day for 15 days
- 5-hydroxytryptophan: 100 mg three times daily for 3 months (if fibromyalgia is present)
- L-carnitine: 1-2 grams three times daily for 3 months
- Coenzyme Q10: 100 mg/day for 3 months
- Essential fatty acids: 280 mg GLA and 135 mg EPA daily for 3 months
The supplements should be administered with medical supervision and accompanied by a high-
potency
vitamin/mineral supplement for the duration of the trial. [95 references]
Werbach, Melvyn R. Nutritional strategies for treating chronic fatigue syndrome. Alternative
Medicine
Review, Vol. 5, No. 2 April 2000, pp. 93-108
Magnesium deficiency linked to diabetes
BALTIMORE, MARYLAND. A link between low body levels of magnesium and type 2 diabetes
has long
been suspected, but there has been no agreement as to whether low magnesium levels cause
diabetes or
the presence of diabetes results in low magnesium levels. A team of researchers from the Johns
Hopkins
University School of Medicine and three other medical schools have just released a major report
which
clearly supports the idea that low magnesium levels are an important risk factor for diabetes.
Their study
involved 12,128 middle-aged white and black Americans who were non-diabetic at the start of the
study. Six
years later 367 of the black participants (14 per cent) and 739 (8 per cent) of the white
participants had
developed diabetes. A comparison of baseline blood serum levels and the incidence of diabetes
showed
that among white participants those with high magnesium levels (greater than 0.95 mmol/L) had a
50 per
cent lower incidence of diabetes than participants with low levels (0.25-0.70 mmol/L). Total
incidence was
11.1 cases per 1000 person-years at the high level and 22.8 cases at the low level. No
significant
correlation between serum magnesium levels and diabetes was found among the black
participants.
Surprisingly, the researchers also did not find any association between dietary intake of
magnesium and the
incidence of diabetes. Other studies have, however, found such a correlation. The researchers
suggest
that increased magnesium consumption along with modification of other risk factors for type 2
diabetes
(obesity and lack of exercise) might represent a novel means to prevent type 2 diabetes.
Kao, W.H. Linda, et al. Serum and dietary magnesium and the risk of type 2 diabetes mellitus.
Archives of
Internal Medicine, Vol. 159, October 11, 1999, pp. 2151-59
Orchard, Trevor J. Magnesium and type 2 diabetes mellitus. Archives of Internal Medicine, Vol.
159,
October 11, 1999, pp. 2119-20 (editorial)
Lack of magnesium and heart disease
ATLANTA, GEORGIA. Researchers at the Centers for Disease Control and Prevention have just
released
the results of a study which shows a clear association between low blood serum levels of
magnesium and
the risk of dying from heart disease and other causes. The study involved 12,000 participants
who were
enrolled between 1971 and 1975 and followed for 19 years. At the end of the study 4282 of the
participants
had died, 1005 of them from ischemic heart disease. Compared with participants having a
magnesium level
of 0.80 mmol/L or less the risk of dying from heart disease was 21 per cent lower among
participants with
magnesium concentrations between 0.80 and 0.84 mmol/L and 31 to 34 per cent lower among
participants
with concentrations higher than 0.84 mmol/L. This correlation held true even after adjusting for
other major
variables such as age, sex, race, education, smoking status, systolic blood pressure, use of anti-
hypertensive medications, body mass index, history of diabetes, alcohol use, and the level of
physical
activity. The researchers estimate that about 11 per cent of the almost 500,000 deaths from
coronary heart
disease which occurred in 1993 in the United States can be attributed to low magnesium levels.
They also
point out that a recent study (NHANES I) found that about 23 per cent of the people evaluated
had
magnesium levels below 0.80 mmol/L. Other studies have shown that a large proportion of the
American
population does not consume the recommended daily allowance of magnesium (350 mg/day for
men and
280 mg/day for women).
Ford, Earl S. Serum magnesium and ischaemic heart disease: findings from a national sample of
US adults.
International Journal of Epidemiology, Vol. 28, August 1999, pp. 645-51
Magnesium supplementation helps heart patients
LOS ANGELES, CALIFORNIA. Clinical trials have shown that a magnesium injection can reduce
the risk of
dying during a heart attack. Whether orally administered magnesium is of benefit to heart
patients is
unclear. Now researchers at the Cedars-Sinai Medical Center report that daily oral magnesium
supplementation may help prevent the formation of blood clots in patients suffering from coronary
artery
disease (CAD). Their experiment involved 42 CAD patients who were randomized to receive
either
magnesium oxide tablets (800-1200 mg/day) or a placebo for a three-month period followed by a
four-week
washout period, and then the alternative treatment for three months. All patients were taking
aspirin as well
as their other regular medications throughout the study. Before and after each phase the
researchers
measured a range of blood chemistry variables among them platelet-dependent thrombosis
(PDT) which is a
measure of the blood's tendency to form clots. The average (median) PDT was found to be 35
per cent
lower in patients taking magnesium than in patients taking the placebo. It is interesting that the
researchers
found no significant differences in blood serum magnesium levels even after three months of
supplementation. This confirms that blood serum is a very poor indicator of magnesium status in
the body.
This is perhaps not surprising as 99 per cent of the body's magnesium content is found in bones
and cells
rather than in the blood. The researchers conclude that oral magnesium supplementation may
benefit CAD
patients. NOTE: This study was partly funded by Blaine Company Inc. (supplier of magnesium
oxide),
Erlanger, KY and Nutrition 21, San Diego, CA.
Shechter, Michael, et al. Oral magnesium supplementation inhibits platelet-dependent
thrombosis in
patients with coronary artery disease. American Journal of Cardiology, Vol. 84, July 15, 1999, pp.
152-
56
Magnesium supplementation reduces bone loss
LOMA LINDA, CALIFORNIA. It is generally assumed that an adequate calcium intake is
essential in
promoting the achievement of peak bone mass in growing children and young adults. Now
researchers at
the University of Graz Medical School in Austria and the Loma Linda University in California
suggest that an
adequate magnesium intake may be equally important. About half the body's reservoir of
magnesium is
found in soft tissue while the other half is found in bone. Excess magnesium is excreted in the
urine. The
researchers recently completed an experiment in which 12 healthy, young men received 350 mg
of
magnesium as a daily oral supplement for a 30-day period. A comparison of the level of
biomarkers for
bone turnover in the supplemented group and in an age-matched control group showed a
statistically
significant decrease in the level of these biomarkers in the supplemented group. Neither the
supplement
group nor the control group were deficient in magnesium and had a dietary intake of about 300
mg/day
(RDA is 300-350 mg/day). The researchers conclude that magnesium supplementation (over and
above the
current RDA) may suppress bone turnover in young adults and speculate that it may also help
prevent age-
related osteoporosis.
Dimai, H.P., et al. Daily oral magnesium supplementation suppresses bone turnover in young
adult males.
Journal of Clinical Endocrinology and Metabolism, Vol. 83, August 1998, pp. 2742-48
Sports drinks lack magnesium
HONOLULU, HAWAII. Dr. Robert Whang MD, Professor of Medicine at the University of Hawaii,
believes
that commonly available sports drinks like Gatorade, Allsport and Powerade are less than
optimum for
rehydration purposes because they contain no magnesium. Dr. Whang points out that adequate
levels of
intracellular potassium and magnesium are important in ensuring sufficient blood flow to the
muscles and
internal organs, in maintaining normal acid-base balance, and in controlling the level of excitation
of the
nerves, particularly in the heart. Magnesium is a vital component in the synthesis of ATP (the
body's main
energy source), DNA, RNA and protein, and is required for proper nerve conduction, muscle
contraction, cell
division, and transport across cell membranes. Magnesium losses during strenuous exercise can
be quite
considerable and are accompanied by significant losses of potassium as well. There is also
some evidence
that a magnesium deficiency can interfere with the reuptake of potassium after dehydration. The
United
States Army has recently developed a new rehydration beverage specifically designed for troops
operating
in desert and tropical environments. The new drink, Army CE 1, contains 128 mg of sodium, 96
mg of
potassium, and 16 mg of magnesium per 240 ml. In comparison the popular sports drink
Gatorade contains
110 mg of sodium, 30 mg of potassium, and no magnesium. Dr. Whang concludes that
consideration
should be given to adding magnesium to sports drinks. He points out that the American diet is
usually
deficient in magnesium and suggests that people engaged in strenuous sports activities
supplement with the
RDA (Recommended Daily Allowance) for magnesium (350 mg/day for men and 280 mg/day for
women in
the USA) provided they do not suffer from kidney failure.
Whang, Robert. Electrolyte and water metabolism in sports activities. Comprehensive Therapy,
Vol. 24,
January 1998, pp. 5-8
Magnesium combats mitral valve prolapse syndrome
WARSAW, POLAND. Mitral valve prolapse syndrome (MVP) is a fairly frequent disorder and is
particularly
prevalent among women of childbearing age. It usually manifests itself through symptoms such
as chest
pain, palpitations, anxiety, headaches, and a low level of vital energy. It can be clinically
confirmed through
an echocardiogram. The cause of MVP is not clear and there is no effective conventional
treatment.
Researchers at the Grochowski Hospital in Warsaw now report that MVP is related to a
magnesium
deficiency and can be successfully treated with oral administration of magnesium supplements.
Their study
involved 141 patients (124 women and 17 men aged 16 to 57 years) whose diagnosis of MVP
had been
confirmed by echocardiography. The researchers measured the serum (blood) level of
magnesium in the
141 patients and in 40 matched, healthy controls. They found that 60 per cent of the MVP
patients had an
abnormally low magnesium level (<0.7 mmol/L) while only five per cent of the controls had a low
level.
Seventy of the patients (64 women and 6 men) were then randomized to receive either oral
magnesium
supplementation or a placebo for a five-week period. The magnesium group received 1800
mg/day of
magnesium carbonate (510 mg of elementary magnesium) for the first week and than 1200
mg/day of
magnesium carbonate (340 mg of elementary magnesium) for the remaining weeks. At the end
of the test
period all participants were evaluated for MVP symptoms, anxiety level, serum magnesium level,
and urine
content of adrenaline and noradrenaline. The average number of MVP symptoms in the patients
treated
with magnesium decreased from 10.4 to 5.6 after treatment. There was no significant change
among the
patients in the placebo group. The number of patients reporting a high level of anxiety decreased
from 32
(54 per cent) to 9 (15 per cent) after supplementation with no change observed in the placebo
group. The
level of noradrenaline excreted in the urine also declined markedly after magnesium
supplementation (from
42 micrograms/gram/24 hours to 26.8 micrograms/gram/24 hours), but increased in the placebo
group. The
researchers conclude that MVP symptoms are linked to a magnesium deficiency and believe that
this
deficiency may be caused by an increased release of adrenaline and noradrenaline in MVP
patients. They
also conclude that magnesium supplementation is effective in combatting MVP symptoms
particularly
anxiety. They speculate that this beneficial effect could be due to magnesium's ability to inhibit
the toxic
effects of an excessive release of catecholamines (adrenaline and noradrenaline).
Lichodziejewska, Barbara, et al. Clinical symptoms of mitral valve prolapse are related to
hypomagnesemia
and attenuated by magnesium supplementation. American Journal of Cardiology, Vol. 79, March
15, 1997,
pp. 768-72
Magnesium reduces cerebral palsy risk
ATLANTA, GEORGIA. Cerebral palsy is a serious muscle disorder caused by brain anomalies
which affects
babies even before they are born. It is particularly prevalent among very low-birth-weight babies
(weight
less than 1500 g at birth). These babies are also at much greater risk of being mentally retarded.
Researchers at the Centers for Disease Control and Prevention now report that administration of
magnesium sulfate to pregnant women prior to giving birth reduces dramatically the incidence of
cerebral
palsy and mental retardation among very low-birth-weight infants. Their study involved over 1000
very low-
birth-weight infants born live in the Atlanta region between April 1986 and March 1988. The
researchers
found that babies born to mothers who had been given magnesium sulfate for pregnancy
complications
were 10 times less likely to be born with cerebral palsy and more than three times less likely to be
born with
mental retardation than were babies born to mothers who had not been given magnesium sulfate
prior to
giving birth. The researchers conclude that giving magnesium sulfate to all mothers in danger of
delivering a
very low-birth-weight infant might prevent 63 per cent of all cases of cerebral palsy and 49 per
cent of all
cases of mental retardation in low-birth-weight babies. They caution though that some women
may have
contraindications to magnesium sulfate therapy.
Schendel, Diana E., et al. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or
mental
retardation among very low-birth-weight children aged 3 to 5 years. Journal of the American
Medical
Association, Vol. 276, No. 22, December 11, 1996, pp. 1805-10
Nelson, Karin B. Magnesium sulfate and risk of cerebral palsy in very low-birth-weight infants.
Journal of
the American Medical Association, Vol. 276, No. 22, December 11, 1996, pp. 1843-44
(editorial)
Muscle cramps cured with magnesium
ST. JOHN'S, CANADA. Canadian doctors report on two cases of severe muscle cramps which
were
relieved by the intravenous infusion of magnesium sulfate. The first case involved a 17-year-old
soldier who
had been exercising too strenuously and developed muscle spasms so severe that he was
immobilized.
The soldier was hospitalized and underwent a battery of tests. The only abnormality found was a
low
concentration of magnesium in the blood serum (0.54 mmol/L vs. a normal range of 0.7 to 1.5
mmol/L). The
soldier was given two intravenous infusions of magnesium sulfate in a saline solution. His pain
lessened
significantly within 48 hours and was gone after four days. The second case involved an 81-year-
old woman
who was hospitalized with abdominal cramps so severe that even injections of Demerol and
morphine could
not subdue the pain. Laboratory tests showed a significant magnesium deficiency (serum level
was 0.50
mmol/L). The patient was given a slow intravenous infusion of five grams of magnesium sulfate
in a 2000 ml
N saline solution over a 24-hour period. She was completely pain-free by the third day and was
discharged
after another week "never feeling better for years". The doctors conclude that diuretic therapy
(with
furosemide) was almost certainly the cause of this latter case of muscle cramps. They also
recommend that
physicians do a magnesium level check whenever patients complain of muscle cramps, muscle
weakness or
neuromuscular dysfunction. Oral supplements have also been found effective in treating muscle
cramps
with the preferred form being magnesium glucoheptonate or magnesium gluconate.
Bilbey, Douglas L.J. and Prabhakaran, Victor M. Muscle cramps and magnesium deficiency:
case reports.
Canadian Family Physician, Vol. 42, July 1996, pp. 1348-51
Magnesium deficiency linked to diabetes
NEW YORK, NY. Researchers at Columbia University report that as many as one in three
diabetics may
lack magnesium. Magnesium deficiencies have also been implicated in cardiac arrhythmias,
vasospasms,
and seizures. It is believed that a lack of magnesium leads to increased insulin resistance, ie. a
faulty
metabolism of carbohydrates that causes unoxidized sugar to accumulate in the blood and urine
(diabetes
mellitus). Although the increase in insulin resistance caused by magnesium deficiency is most
pronounced
in diabetics it can also occur in non-diabetics. Furthermore, it is now clear that magnesium
absorption is
impaired in diabetics thus setting up a vicious cycle of magnesium deficiency and insulin
resistance. The
researchers believe that insulin-dependent diabetics can benefit substantially from oral
supplementation with
magnesium (hydroxide or chloride). They also point out that magnesium supplementation (six
weeks of
magnesium chloride, 384 mg/day) has been found to lower systolic blood pressure in type II
diabetics (by
about 7 mm Hg). The recommended magnesium intake for adults is 300-400 mg/day, but
significantly
higher intakes may be required to correct severe depletion. Supplementation is not
recommended for
patients with kidney disease.
Tosiello, Lorraine. Hypomagnesemia and diabetes mellitus. Archives of Internal Medicine, Vol.
156, June
10, 1996, pp. 1143-48
Magnesium in drinking water prevents heart attacks
GOTHENBURG, SWEDEN. Previous studies have shown that there is a significant correlation
between
mortality from cardiovascular disease and drinking water hardness. Now Swedish researchers
report that
men who live in areas where the drinking water has a high content of magnesium are much less
likely to
suffer a heart attack than are men who live in areas with a low content. Their study involved 854
men who
had died from a heart attack between ages 50 and 69 years and 989 age-matched controls who
died from
cancer during the seven-year study period. All the men lived within a well defined study area in
which the
drinking water was supplied by 17 different municipal water works. The magnesium content of
the water
supply varied significantly between the municipalities, but had not changed over a 10-year period.
The
researchers found that the incidence of fatal heart attacks was 35 per cent lower in areas where
the
magnesium content of the drinking water was 9.8 mg/liter or more than in areas where the
content was 3.5
mg/liter or less. The calcium content of the water was not significantly associated with the
incidence of fatal
heart attacks. The researchers believe that magnesium protects against fatal heart attacks
through its ability
to prevent arrhythmias and artery spasms. They also point out that many people are magnesium
deficient
and that drinking water with a high magnesium content may just be enough to help prevent heart
attacks.
Magnesium in water is more easily absorbed than magnesium in food. The absorption of
magnesium is
significantly affected by the simultaneous intake of other nutrients such as sugar, phytates,
saturated fats,
proteins, calcium, and phosphates.
Rubenowitz, Eva, et al. Magnesium in drinking water and death from acute myocardial infarction.
American
Journal of Epidemiology, Vol. 143, No. 5, March 1, 1996, pp. 456-62
Magnesium effective in treatment of osteoporosis
ADELAIDE, AUSTRALIA. Dr. Ivor Dreosti of the Commonwealth Scientific and Industrial
Research
Organization has just released a major report detailing the current knowledge of the importance
of
magnesium in human nutrition. Magnesium is involved in the functioning of more than 200
enzymes and is
a key player in the body's energy (ATP) cycle. The recommended dietary intake is 300-400
mg/day (in the
U.S.A.), an amount which many scientists now feel may be insufficient. It is also clear that many
people do
not even get the recommended intake and that this can lead to problems with muscle spasms
and idiopathic
mitral valve prolapse. Dr. Dreosti points out that the body's requirement is increased markedly by
both
stress and vigorous exercise. Recent tests have also shown that exercise capacity can be
significantly
increased by the use of magnesium supplements. Many researchers are now also reporting that
magnesium deficiency plays a significant role in the development of osteoporosis. Studies have
shown that
women suffering from osteoporosis tend to have a lower magnesium intake than normal and also
have lower
levels of magnesium in their bones. It is also clear that recommendations to postmenopausal
women to
increase calcium intake can lead to an unfavourable Ca:Mg ratio unless the magnesium intake is
increased
accordingly; the optimum ratio of Ca:Mg is believed to be 2:1. A magnesium deficiency can also
affect the
production of the biologically active form of vitamin D and thereby further promoting osteoporosis.
Some
very recent research shows that magnesium supplementation is effective in treating osteoporosis.
A trial in
Israel showed that postmenopausal women suffering from osteoporosis could stop further bone
loss by
supplementing with 250-750 mg/day of magnesium for two years. Some (8 per cent) of the
treated women
even experienced a significant increase in trabecular bone density. Untreated controls lost bone
mass at
the rate of 1 per cent per year. Another experiment in Czechoslovakia found that 65 per cent of
women who
supplemented with 1500 to 3000 mg of magnesium lactate daily for two years completely got rid
of their pain
and stopped further development of deformities of the vertebrae. Other studies have shown that
magnesium is helpful in the treatment of cardiac arrhythmias and that an adequate intake may
help prevent
atherosclerosis.
Dreosti, Ivor E. Magnesium status and health. Nutrition Reviews, Vol. 53, No. 9, September
1995, pp. S23-
S27
Natural mineral salt lowers blood pressure
ROTTERDAM, NETHERLANDS. Medical researchers at the Erasmus University Medical School
have
discovered a natural mineral salt which significantly lowers blood pressure in people suffering
from mild to
moderate hypertension. The salt, "SagaSalt" (Akzo Nobel, Netherlands) occurs naturally in
Iceland and
contains 41 per cent sodium chloride, 41 per cent potassium chloride, 17 per cent magnesium
salts and 1
per cent trace minerals. The researchers tested the salt in a randomized double blind placebo
controlled
trial involving 100 men and women aged 55 to 75 years. The participants had systolic blood
pressures
between 140 and 200 mm Hg or diastolic pressures between 85 and 100 mm Hg. Half the group
used the
mineral salt in food preparation and at the table while the other half used common table salt
(sodium
chloride). Blood pressures were measured at the start of the experiment and after 8, 16 and 24
weeks.
After eight weeks the average blood pressure in the mineral salt group had fallen significantly.
The systolic
blood pressure (mean of measurement at weeks 8, 16 and 24) fell by 7.6 mm Hg and the diastolic
pressure
by 3.3 mm Hg in the mineral salt group as compared with the control group. After 24 weeks all
participants
went back to using common table salt and at week 25 there was no longer any difference in blood
pressures
between the two groups. The researchers conclude that replacing common table salt with a low
sodium,
high potassium, high magnesium mineral salt is an effective way of lowering blood pressure in
older people
suffering from mild to moderate hypertension. NOTE: Systolic pressure is the first (highest)
reading given in
a blood pressure measurement, diastolic is the second (lowest) reading, i.e. 120/80.
Geleijnse, J.M., et al. Reduction in blood pressure with a low sodium, high potassium, high
magnesium salt
in older subjects with mild to moderate hypertension. British Medical Journal, Vol. 309, August
13, 1994, pp.
436-40
Magnesium deficiency: A risk factor for asthma?
NOTTINGHAM, ENGLAND. Researchers at the University of Nottingham have concluded that a
high intake
of magnesium is associated with a better lung function and a reduced risk of airway hyper-
reactivity and
wheezing. Their study involved 2633 adults aged 18 to 70 years whose average daily
magnesium intake
was 380 mg as estimated via a diet questionnaire. The actual magnesium intake varied widely
from 182 to
654 mg/day in men and from 160 to 527 mg/day for women. The researchers estimate that the
daily steady
state requirement may be as high as 420 mg/day and conclude that a substantial proportion of
adults in the
U.K. are deficient in their magnesium intake. They also conclude from their experiment that the
lung
capacity (forced expiratory volume) of participants who had a 100 mg/day higher than average
intake of
magnesium was significantly better than among participants with a lower intake. Participants who
consumed more magnesium also reported less wheezing within the preceding 12 months and
showed less
reactivity when challenged with a methacholine spray. The researchers conclude that a
magnesium
deficiency may be implicated in the development of asthma and other chronic obstructive airways
diseases.
Britton, John, et al. Dietary magnesium, lung function, wheezing, and airway hyper-reactivity in a
random
adult population sample. The Lancet, Vol. 344, August 6, 1994, pp. 357-62
Magnesium supplement lowers blood pressure
ROTTERDAM, THE NETHERLANDS. A double-blind controlled trial was recently carried out by
Dutch and
Belgian researchers in order to determine if oral supplementation with magnesium is an effective
way of
lowering blood pressure in women suffering from mild to moderate hypertension. Their
experiment involved
91 women between 35 and 77 years of age who did not take anti-hypertensive medication. All
the women
had a systolic blood pressure between 140 and 185 mm Hg and a diastolic pressure between 90
and 105
mm Hg. After a two-week period where all subjects received a placebo, the participants were
randomly
assigned to two groups. One group continued to receive the placebo while the other group
received 485 mg
per day of magnesium aspartate-HCl. Both the placebo and the magnesium supplement were
supplied in
the form of four packets of water-soluble powder per day to be taken with meals. At the end of
the six-
month trial period the systolic blood pressure in the magnesium supplementation group had
decreased by
2.7 mm Hg and the diastolic pressure by 3.4 mm Hg when compared to the placebo group. The
researchers
conclude that oral supplementation with magnesium aspartate-HCl may be effective in lowering
blood
pressure in people suffering from mild to moderate hypertension who are not taking anti-
hypertensive
drugs.
Witteman, Jacqueline C.M., et al. Reduction of blood pressure with oral magnesium
supplementation in
women with mild to moderate hypertension. American Journal of Clinical Nutrition, Vol. 60, July
1994, pp.
129-35
Magnesium prevents death from heart attack
LEICESTER, ENGLAND. Medical doctors at the Leicester Royal Infirmary report that the
previously found
reduction in mortality among heart attack patients injected with magnesium sulfate is long term in
nature.
The doctors' original study involved 2316 randomly selected heart attack victims. Half of the
patients were
given 8 mmol of magnesium sulfate injected intravenously over five minutes within three hours or
less of the
first symptoms of the attack; this was followed by a total of 65 mmol of magnesium sulfate
supplied by
constant infusion over a 24-hour period. The placebo group received the same amount of saline
solution.
After 28 days, 24 per cent fewer patients in the magnesium group had died than in the placebo
group. The
doctors followed up on all the patients for an average of 2.7 years (1.0 - 5.5 years) and now
report that the
longer term mortality rate from ischaemic heart disease was reduced by 21 per cent and the all-
cause
mortality rate by 16 per cent in the magnesium-treated patients. The researchers point out that it
is
important that the magnesium be administered quickly (within three hours of onset of symptoms)
and before
the start of thrombolytic therapy.
Woods, Kent L. and Fletcher, Susan. Long-term outcome after intravenous magnesium sulphate
in
suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention
Trial
(LIMIT-2). The Lancet, Vol. 343, April 2, 1994, pp. 816-19
Magnesium helps patients with heart failure
CHAPEL HILL, NORTH CAROLINA. Researchers at the University of North Carolina have found
that
magnesium injections lower the frequency and severity of ventricular arrhythmias in patients with
heart
failure. Twenty-one men and nine women aged 49 +9.6 years participated in the double-blind,
placebo-
controlled crossover experiment. The active treatment consisted of one injection of 0.3 mEq/kg
magnesium
chloride in 5 per cent dextrose in water followed by continuous infusion of a dextrose/water
magnesium
chloride solution (0.08 mEq/kg per hour) over 24 hours. The placebo treatment was similar
except that the
magnesium chloride was omitted from the dextrose/water solution. The number of PVCs
(premature
ventricular contractions) per hour was reduced by 53 per cent in the magnesium group as
compared to the
placebo group; the number of episodes of ventricular tachycardia was reduced by 69 per cent
and in the
patients who did have such episodes the heart rate was significantly lower than during placebo
treatment
(143 beats/minute vs. 179 beats/minute). The researchers recommend that a larger study be
undertaken to
determine if oral administration of magnesium would have similar benefits.
Sueta, Carla A., et al. Effect of acute magnesium administration on the frequency of ventricular
arrhythmia
in patients with heart failure. Circulation, Vol. 89, No. 2, February 1994, pp. 660-66
Magnesium saves lives
LEICESTER, ENGLAND. Reports of the beneficial effects of the use of magnesium in the
treatment of heart
attack patients date back to the 1960s. More recent studies show a possible 25% reduction in
mortality
among patients injected with magnesium. Now a large study carried out at the Leicester Royal
Infirmary in
England confirms the beneficial effects. The experiment involved 2316 randomly selected heart
attack
victims. Half of the patients were given an injection of 8 mmol of magnesium sulfate injected
intravenously
over 5 minutes followed by a total of 65 mmol supplied by constant infusion over a 24-hour
period. The
placebo group received the same amount of saline solution. After 28 days, 90 of the 1150
patients treated
with magnesium had died as compared to 118 of the 1150 patients in the placebo group. This
corresponds
to a 24% reduction in mortality. Researchers involved in the studies conclude that magnesium
injection is a
safe, effective, and inexpensive therapy in the management of myocardial infarction (heart
attack).
Yusuf, Salim, et al. Intravenous magnesium in acute myocardial infarction. Circulation, Vol. 87,
No. 6, June
1993, pp. 2043-46
Magnesium helps recovery after bypass surgery
BALTIMORE, MARYLAND. Patients having undergone coronary bypass surgery often suffer
from
ventricular dysrhythmias and decreased stroke volume immediately after the operation. Medical
doctors at
the Sinai Hospital of Baltimore have now found that supplementation with magnesium markedly
decreases
the frequency of these serious complications. One hundred patients were studied over a 6-month
period; 50
were given an intravenous infusion of magnesium chloride (2 grams) immediately after the
operation while
the other 50 were given a placebo. The magnesium treated patients suffered significantly fewer
ventricular
dysrhythmias (16% vs. 34%) than did the untreated patients.
Journal of the American Medical Association, November 4, 1992, pp. 2395-2402
Dietary fiber and magnesium prevent hypertension
BOSTON, MASSACHUSETTS. Doctors at the Harvard School of Public Health have completed
a study to
determine the relationship between diet and hypertension (high blood pressure). The study
involved over
30,000 male health professionals 40 to 75 years old. The baseline mean systolic blood pressure
for the
men was 125.5 mm at age 40-44 and 133.7 mm at age 70-75. The diastolic blood pressure at
79.3 to 80.4
mm was relatively unchanged with age. During four years of follow-up 1248 of the men
developed
hypertension. An analysis showed that participants consuming less than 250 mg per day of
magnesium had
a 50% greater chance of developing hypertension than had men who consumed 400 mg/day or
more.
Similarly, an intake of less than 2.4 g/day of potassium increased the risk of hypertension by 50%
as
compared to an intake of 3.6 g/day or more. The most striking effect was found in the case of
dietary fiber
where an intake of 24 grams/day or more was found to provide significant protection. A higher
intake of
dietary fiber, magnesium, and potassium was also found to be associated with lower blood
pressure in
healthy men. The results of this study confirm the findings of an earlier study involving 58,000
nurses. The
authors point out that although diet is important in preventing hypertension, its effect is
overshadowed by the
risk imposed by obesity and excessive alcohol intake.
Circulation, November 1992, pp. 1475-84
Magnesium deficiency and heart disease go together
TUCSON, ARIZONA. Researchers at the University Medical Center in Tucson have confirmed
that
magnesium deficiency is closely associated with cardiovascular disease. Lowered serum
magnesium
concentrations have been found in heart attack patients and administration of magnesium has
proven
beneficial in treating ventricular arrhythmias, particularly those caused by digoxin
toxicity.
American Heart Journal, October 1992, pp. 1113-18
Magnesium may prevent fatal heart attacks
SAN FRANCISCO, CALIFORNIA. Sudden fatal heart attacks claim over 300,000 victims each
year in the
U.S. alone. Fatal heart attacks are more common in areas where the water supply is magnesium
deficient.
Dr. Eisenberg at the University of California now suggests that there is a definite link between
magnesium
deficiency and sudden fatal heart attacks. He points out that the average human body contains
about 24
grams of magnesium and requires a daily intake of 200-400 milligrams. The actual average
intake through
food and drinking water is often significantly less than the requirement particularly in areas having
a supply
of soft drinking water. The doctor recommends large scale studies to evaluate the potential
benefits of oral
magnesium supplementation.
American Heart Journal, August 1992, pp. 544-49